The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 1, 2012, Pages 103-109

  Higgins, Deborah L ^a   Ero, Mike P ^b   Loeb, Michelle ^c   Kersey, Kathryn ^c   Hopkins, Alan ^c   Beattie, David T ^c  

^a DL Higgins Consulting   (United States)

^b Machaon Diagnostics Inc   (United States)

^c THERAVANCE INC   (United States)

Author keywords

Cardiovascular ischemia; Coronary artery; Platelet aggregation; Tegaserod

Indexed keywords

ADENOSINE DIPHOSPHATE; TEGASEROD; THROMBOPOIETIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DOG; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; ISCHEMIA; MALE; NONHUMAN; SWINE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TREATMENT OUTCOME;

ADENOSINE DIPHOSPHATE; ADULT; ANIMALS; CORONARY VESSELS; DOGS; FEMALE; HUMANS; INDOLES; ISOMETRIC CONTRACTION; MALE; MIDDLE AGED; PLATELET AGGREGATION; SEROTONIN; SEROTONIN RECEPTOR AGONISTS; SWINE; YOUNG ADULT;

EID: 84857031281     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0687-x     Document Type: Article

References (25)

1. JL Anderson HT May TI Bair, et al. 2009 Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study J Cardiovasc Pharmacol Theraput 14 170 175 10.1177/1074248409340158 1:CAS:528:DC%2BD1MXhtFGgs7jM
2. 2B receptor antagonist in vitro and in vivo Br J Pharmacol 143 549 560 15466450 10.1038/sj.bjp.0705929 1:CAS:528:DC%2BD2cXhtVWitL7J (Pubitemid 39524272)
3. 4 receptor agonist with high intrinsic activity Naunyn Schmiedeberg's Arch Pharmacol 378 139 147 10.1007/s00210-008-0281-z 1:CAS:528:DC%2BD1cXnsVSmu7o%3D
4. MR Briejer LMA Akkermans JAJ Schuurkes 1995 Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility Pharmacol Rev 47 631 651 8746557 1:CAS:528:DyaK28Xlt1Cktw%3D%3D (Pubitemid 26006144)
5. 4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists J Med Chem 38 2331 2338 7608899 10.1021/jm00013a010 1:CAS:528:DyaK2MXmtVyhsLc%3D
6. M Camilleri 2001 Review article: tegaserod Aliment Pharmacol Theraput 15 277 289 10.1046/j.1365-2036.2001.00925.x 1:CAS:528:DC%2BD3MXit1ers70%3D (Pubitemid 32187551)
7. I Carel B Ghaleh A Edouard, et al. 2001 Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs Br J Pharmacol 132 1071 1083 11226138 10.1038/sj.bjp.0703917 1:CAS:528:DC%2BD3MXitFKnsb8%3D (Pubitemid 32238913)
8. KY Chan R de Vries FPJ Leijten, et al. 2009 Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries Eur J Pharmacol 619 61 67 19619527 10.1016/j.ejphar.2009.07.010 1:CAS:528:DC%2BD1MXhtFajsLjO
9. Clinical and Laboratory Standards Institute (2008) Platelet function testing by aggregometry; approved guideline. Document H58-A, Wayne
10. JH De Maeyer RA Lefebvre JA Schuurkes 2008 5-HT(4) receptor agonists: similar but not the same Neurogastroenterol Motil 20 99 112 18199093 10.1111/j.1365-2982.2007.01059.x
11. L Gerson 2007 Comment Gastroenterol 133 721 722
12. H Gong T Nakamura K Hattori, et al. 2000 A novel 5-HT(2) antagonist, sarpogrelate hydrochloride, shows inhibitory effects on both contraction and relaxation mediated by 5-HT receptor subtypes in porcine coronary arteries Pharmacol 61 263 268 10.1159/000028411 1:CAS:528:DC%2BD3cXosFKqtb4%3D
13. Jennings LK, White MM (2007) Platelet aggregation. In: Michelson AD (ed) Platelets, 2nd edn. Elsevier, Amsterdam, pp 495-518
14. JF Johanson 2004 Review article: tegaserod for chronic constipation Aliment Pharmacol Theraput 20 suppl 7 20 24 10.1111/j.1365-2036.2004.02187.x 1:CAS:528:DC%2BD2MXmsFWmsg%3D%3D (Pubitemid 39657672)
15. J Louglin S Quinn E Rivero, et al. 2010 Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study J Cardiovasc Pharmacol Theraput 15 151 157 10.1177/1074248409360357
16. (4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Aliment Pharmacol Theraput 15 1655 1666 10.1046/j.1365-2036.2001.01094.x 1:CAS:528:DC%2BD3MXnvVCgsL4%3D (Pubitemid 32912410)
17. T Nilsson J Longmore D Shaw, et al. 1999 Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques Eur J Pharmacol 372 49 56 10374714 10.1016/S0014-2999(99)00114-4 1:CAS:528:DyaK1MXjs1ehtbk%3D (Pubitemid 29229863)
18. A Oda Y Miyakawa BJ Druker, et al. 1996 Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists Blood 87 4664 4670 8639835 1:CAS:528:DyaK28Xjt1equ7w%3D (Pubitemid 26162365)
19. JJ Podczasy J Lee I Vucenik 1997 Evaluation of whole-blood lumiaggregation Clin Appl Thromb Hemost 3 190 195 10.1177/107602969700300307 (Pubitemid 28166810)
20. H Riess G Braun E Hiller 1986 Critical evaluation of platelet aggregation in whole human blood Am J Clin Pathol 85 50 56 3079628 1:STN:280: DyaL28%2FnsVSmuw%3D%3D (Pubitemid 16166040)
21. 4 receptor expression and effects of tegaserod on human platelet aggregation in vitro Am J Therap 17 543 552 10.1097/MJT.0b013e3181b63f21
22. 1D alpha receptor subtype expression in canine large coronary arteries and saphenous vein Cardiovasc Res 31 793 799 8763409 1:CAS:528:DyaK28Xkt1Knt7w%3D
23. 4 receptor agonist with high intrinsic activity Naunyn Schmiedeberg's Arch Pharmacol 378 125 137 10.1007/s00210-008-0282-y 1:CAS:528:DC%2BD1cXnsVSmu7g%3D
24. L Zhou AH Schmaier 2005 Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field Am J Clin Pathol 123 172 183 15842039 10.1309/Y9EC63RW3XG1V313 (Pubitemid 40194076)
25. MB Zucker 1989 Platelet aggregation measured by the photometric method Meth Enzymol 169 117 133 2716524 10.1016/0076-6879(89)69054-4 1:CAS:528:DyaL1MXkslCitrg%3D (Pubitemid 19101525)